Postexposure Rabies Prophylaxis Completed in 1 Week: Preliminary Study

Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made a...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 50; no. 1; pp. 56 - 60
Main Authors Shantavasinkul, Prapimporn, Tantawichien, Thanphet, Wilde, Henry, Sawangvaree, Artikaya, Kumchat, Apinya, Ruksaket, Natthasri, Lohsoonthorn, Vitool, Khawplod, Pakamatz, Tantawichien, Terapong
Format Journal Article
LanguageEnglish
Published Oxford The University of Chicago Press 01.01.2010
University of Chicago Press
Oxford University Press
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. Methods We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Results Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P <.001). All subjects in all groups had a NAb value ⩾0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value ⩾0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. Conclusions After any PEP regimen, World Health Organization recommendations require a NAb value ⩾0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.
AbstractList Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. Methods We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Results Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P <.001). All subjects in all groups had a NAb value ⩾0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value ⩾0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. Conclusions After any PEP regimen, World Health Organization recommendations require a NAb value ⩾0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.
Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. We administered the 4 ... site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2 ... site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Geometric mean titers for subjects receiving the 4 ... site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P < .001). All subjects in all groups had a NAb value ≥0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value ≥0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. After any PEP regimen, World Health Organization recommendations require a NAb value ≥0.5 IU/mL on days 14 and 28. The 1 ... week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2 ... site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume. (ProQuest: ... denotes formulae/symbols omitted.)
Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week.BACKGROUNDPatients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week.We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360.METHODSWe administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360.Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P<.001). All subjects in all groups had a NAb value > or =0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value > or =0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups.RESULTSGeometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P<.001). All subjects in all groups had a NAb value > or =0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value > or =0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups.After any PEP regimen, World Health Organization recommendations require a NAb value > or =0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.CONCLUSIONSAfter any PEP regimen, World Health Organization recommendations require a NAb value > or =0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.
Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P<.001). All subjects in all groups had a NAb value > or =0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value > or =0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. After any PEP regimen, World Health Organization recommendations require a NAb value > or =0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.
Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. Methods We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Results Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P <.001). All subjects in all groups had a NAb value ⩾0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value ⩾0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. Conclusions After any PEP regimen, World Health Organization recommendations require a NAb value ⩾0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.
Background. Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week. Methods. We administered the 4-site Intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site Intradermai injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360. Results. Geometric mean liters for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P < .001). All subjects in all groups had a NAb value .0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value .0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups. Conclusions. After any PEP regimen, World Health Organization recommendations require a NAb value .=0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It Increased immunogeniclty over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.
Author Lohsoonthorn, Vitool
Tantawichien, Terapong
Wilde, Henry
Ruksaket, Natthasri
Kumchat, Apinya
Tantawichien, Thanphet
Shantavasinkul, Prapimporn
Sawangvaree, Artikaya
Khawplod, Pakamatz
Author_xml – sequence: 1
  givenname: Prapimporn
  surname: Shantavasinkul
  fullname: Shantavasinkul, Prapimporn
  email: sprapimporn@gmail.com
  organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand
– sequence: 2
  givenname: Thanphet
  surname: Tantawichien
  fullname: Tantawichien, Thanphet
  organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand
– sequence: 3
  givenname: Henry
  surname: Wilde
  fullname: Wilde, Henry
  organization: Division of Research Affairs, Chulalongkorn University, Bangkok, Thailand
– sequence: 4
  givenname: Artikaya
  surname: Sawangvaree
  fullname: Sawangvaree, Artikaya
  organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand
– sequence: 5
  givenname: Apinya
  surname: Kumchat
  fullname: Kumchat, Apinya
  organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand
– sequence: 6
  givenname: Natthasri
  surname: Ruksaket
  fullname: Ruksaket, Natthasri
  organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand
– sequence: 7
  givenname: Vitool
  surname: Lohsoonthorn
  fullname: Lohsoonthorn, Vitool
  organization: Department of Preventive and Social Medicine, Chulalongkorn University, Bangkok, Thailand
– sequence: 8
  givenname: Pakamatz
  surname: Khawplod
  fullname: Khawplod, Pakamatz
  organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand
– sequence: 9
  givenname: Terapong
  surname: Tantawichien
  fullname: Tantawichien, Terapong
  organization: Queen Saovabha Memorial Institute, The Thai Red Cross Society (World Health Organization Collaborating Center for Research on Rabies Pathogenesis and Prevention), Bangkok, Thailand
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22337852$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19995217$$D View this record in MEDLINE/PubMed
BookMark eNqF0l1r1jAUB_AgE_eifgOlCuqN1bz0NIl324NzysDhC47dhDRNMM_apiYt7Pn2ZvRxg4l4lcD58eecnOyjnSEMFqHHBL8hWNRv60pSQu6hPQKMlzVIspPvGERZCSZ20X5Ka4wJERgeoF0ipQRK-B46PgtpsldjSHO0xRfdeJuKsxjGn5tOX_lUrEI_dnaybeGHghQ_rL18l4HtfO8HHTfF12luNw_Rfae7ZB9tzwP0_fj9t9VJefr5w8fV4WlpKmBTqaGhQnNBoZWubo2hDBqLW001uNyQ1JUEV0ODSescSOO4rFwrhWwqJ41mB-jVkjvG8Gu2aVK9T8Z2nR5smJPiUEFFKgb_l4zVQjDCsnx-R67DHIc8hsodyRpLIjN6ukVz09tWjdH3eXr15yUzeLEFOhnduagH49ONo5QxLoBm93JxJoaUonW3UVhdr1Itq8zw9R1o_KQnH4Ypat_9zZ8tPMzjvyOfLGadphBve-M8D4HrXC-Xur_-Ezd1HS9VzRkHdXJ-oQh8Olrxi3Ml2W86V77M
CODEN CIDIEL
CitedBy_id crossref_primary_10_1093_cid_cis389
crossref_primary_10_1371_journal_pntd_0006340
crossref_primary_10_3390_tropicalmed5010040
crossref_primary_10_1016_j_vaccine_2013_07_034
crossref_primary_10_4161_hv_26264
crossref_primary_10_1016_j_tmaid_2011_12_005
crossref_primary_10_1016_j_vaccine_2018_10_054
crossref_primary_10_1038_s41598_020_59109_w
crossref_primary_10_1016_j_meegid_2014_12_024
crossref_primary_10_1007_s44197_022_00080_2
crossref_primary_10_1111_jtm_12022
crossref_primary_10_1016_j_vaccine_2011_12_028
crossref_primary_10_1111_jtm_12167
crossref_primary_10_1371_journal_pntd_0006649
crossref_primary_10_1586_14760584_2014_901893
crossref_primary_10_1586_erv_11_140
crossref_primary_10_1016_j_vaccine_2015_11_036
crossref_primary_10_1016_j_vaccine_2019_01_019
crossref_primary_10_1080_21645515_2015_1048938
crossref_primary_10_2217_fvl_15_26
crossref_primary_10_1016_j_vaccine_2018_11_010
crossref_primary_10_1038_nrdp_2017_91
crossref_primary_10_1371_journal_pntd_0004920
crossref_primary_10_1586_14760584_2014_971764
crossref_primary_10_1016_j_vaccine_2018_11_072
crossref_primary_10_1371_journal_pntd_0000982
crossref_primary_10_1016_j_vaccine_2011_03_106
crossref_primary_10_1016_j_tmaid_2015_05_008
crossref_primary_10_1080_21645515_2021_1957413
crossref_primary_10_1517_14712598_2012_691162
crossref_primary_10_3201_eid1612_100958
crossref_primary_10_1016_j_vaccine_2018_10_103
crossref_primary_10_4161_hv_20471
crossref_primary_10_1016_j_vaccine_2013_06_083
crossref_primary_10_1111_j_1708_8305_2011_00540_x
crossref_primary_10_1093_jtm_tax064
crossref_primary_10_1016_j_vaccine_2019_01_041
crossref_primary_10_1016_j_antiviral_2013_07_004
crossref_primary_10_1038_nm0115_8
crossref_primary_10_1016_j_vaccine_2011_12_133
crossref_primary_10_1097_QCO_0000000000000578
crossref_primary_10_1016_j_vaccine_2021_01_023
ContentType Journal Article
Copyright 2009 Infectious Diseases Society of America
2010 by the Infectious Diseases Society of America 2010
2015 INIST-CNRS
Copyright University of Chicago, acting through its Press Jan 1, 2010
Copyright_xml – notice: 2009 Infectious Diseases Society of America
– notice: 2010 by the Infectious Diseases Society of America 2010
– notice: 2015 INIST-CNRS
– notice: Copyright University of Chicago, acting through its Press Jan 1, 2010
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T2
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
7X8
DOI 10.1086/649211
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Safety Science Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
Virology and AIDS Abstracts
MEDLINE - Academic
MEDLINE


AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1537-6591
EndPage 60
ExternalDocumentID 1922294001
19995217
22337852
10_1086_649211
10.1086/649211
27799506
ark_67375_HXZ_15JBC7ZX_9
Genre Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
Feature
GroupedDBID ---
..I
.2P
.I3
.ZR
08P
0R~
1TH
29B
2AX
2WC
36B
4.4
48X
53G
5GY
5RE
5VS
5WD
6J9
AABZA
AACGO
AACZT
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
ABBHK
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABLJU
ABNGD
ABNHQ
ABOCM
ABPLY
ABPQP
ABPTD
ABQLI
ABQNK
ABTLG
ABVGC
ABWST
ABXSQ
ABXVV
ACGFO
ACGFS
ACHIC
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACYHN
ADBBV
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADQBN
ADQXQ
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AGINJ
AGORE
AGQPQ
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQKUS
AQVQM
ASPBG
ATGXG
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BSCLL
BTRTY
BVRKM
C1A
C45
CDBKE
CS3
CZ4
DAKXR
DCCCD
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
IPSME
J21
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
JXSIZ
KAQDR
KBUDW
KOP
KSI
KSN
L7B
MHKGH
MJL
ML0
N4W
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
ODZKP
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TMA
TR2
W8F
X7H
YAYTL
YKOAZ
YXANX
~91
~S-
AAYOK
AASNB
ADACV
ADJQC
ADRIX
AFXEN
DOOOF
ESX
JSODD
M49
.GJ
1KJ
3O-
70D
AAPGJ
AAPNW
AAWDT
AAYXX
ABKDP
ABNKS
ABSMQ
ABZBJ
ACFRR
ACPQN
ACVCV
ACZBC
ADEYI
ADMTO
ADOCK
AEKPW
AFFQV
AFSHK
AFYAG
AGKEF
AGKRT
AGMDO
AHGBF
AI.
AIJHB
AJDVS
APJGH
AQDSO
AVNTJ
BZKNY
CITATION
EIHJH
HQ3
HTVGU
J5H
MBLQV
OBFPC
O~Y
VH1
Y6R
ZGI
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T2
7T7
7U7
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
7X8
ID FETCH-LOGICAL-c453t-a5b28a7825d9f6dcc235be0da2a5f5219a495f65b01dff59cf794fd989b4f9ca3
ISSN 1058-4838
1537-6591
IngestDate Fri Jul 11 03:15:28 EDT 2025
Fri Jul 11 09:35:00 EDT 2025
Fri Jul 25 02:32:04 EDT 2025
Wed Feb 19 01:47:01 EST 2025
Mon Jul 21 09:14:49 EDT 2025
Thu Apr 24 23:00:15 EDT 2025
Tue Jul 01 01:25:44 EDT 2025
Wed Sep 11 04:51:01 EDT 2024
Thu Jun 19 15:27:37 EDT 2025
Tue Aug 05 16:50:02 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Infection
Prevention
Nervous system diseases
Chemoprophylaxis
Viral disease
Rabies
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c453t-a5b28a7825d9f6dcc235be0da2a5f5219a495f65b01dff59cf794fd989b4f9ca3
Notes istex:6D362E34CC637012713E3AF6EEF5EE39EF4A6947
ark:/67375/HXZ-15JBC7ZX-9
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-2
content type line 23
PMID 19995217
PQID 219960919
PQPubID 48300
PageCount 5
ParticipantIDs proquest_miscellaneous_754541435
proquest_miscellaneous_733688313
proquest_journals_219960919
pubmed_primary_19995217
pascalfrancis_primary_22337852
crossref_primary_10_1086_649211
crossref_citationtrail_10_1086_649211
oup_primary_10_1086_649211
jstor_primary_27799506
istex_primary_ark_67375_HXZ_15JBC7ZX_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-01-01
20100101
2010-01-00
2010
2010-Jan-01
PublicationDateYYYYMMDD 2010-01-01
PublicationDate_xml – month: 1
  year: 2010
  text: 20100101
  day: 1
PublicationDecade 2010
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: United States
PublicationTitle Clinical infectious diseases
PublicationTitleAbbrev Clinical Infectious Diseases
PublicationTitleAlternate Clinical Infectious Diseases
PublicationYear 2010
Publisher The University of Chicago Press
University of Chicago Press
Oxford University Press
Publisher_xml – name: The University of Chicago Press
– name: University of Chicago Press
– name: Oxford University Press
SSID ssj0011805
Score 2.2133353
Snippet Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the...
Background. Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing...
Background Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the...
Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of...
SourceID proquest
pubmed
pascalfrancis
crossref
oup
jstor
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 56
SubjectTerms Adult
Analysis of Variance
Animals
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
ARTICLES AND COMMENTARIES
Biological and medical sciences
Cercopithecus aethiops
Clinical medicine
Disease prevention
Female
Geometric mean
Horses
Human viral diseases
Humans
Immune system
Immunization, Passive - methods
Immunoglobulins
Immunoglobulins - administration & dosage
Infectious diseases
Injections, Intradermal
Male
Medical research
Medical sciences
Middle Aged
Neutralizing antibodies
Nonprofit organizations
Post exposure prophylaxis
Post-Exposure Prophylaxis - methods
Prospective Studies
Rabies
Rabies - immunology
Rabies - prevention & control
Rabies vaccines
Rabies Vaccines - administration & dosage
Rabies Vaccines - adverse effects
Rabies Vaccines - immunology
Vaccination
Vaccines
Vero Cells
Viral diseases
Viral diseases of the nervous system
Title Postexposure Rabies Prophylaxis Completed in 1 Week: Preliminary Study
URI https://api.istex.fr/ark:/67375/HXZ-15JBC7ZX-9/fulltext.pdf
https://www.jstor.org/stable/27799506
https://www.ncbi.nlm.nih.gov/pubmed/19995217
https://www.proquest.com/docview/219960919
https://www.proquest.com/docview/733688313
https://www.proquest.com/docview/754541435
Volume 50
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWMBCgKFEW3tEraVIe2l0CFNkriUXXU2ll8iO3YyEUgKRE1YiiGF8Dp13dISrLcNOlyEQyR1sI3Gs6Qb2YQ-iA86mPuhhaLSGiBSc0txiLfskMiRG7bOWUyGvm8F3SG_skYj1utJmtptWSf-Y_fxpX8D6pwDnCVUbL_gGx9UTgBvwFfOALCcPwrjGWl3Xw9u5GrfEcXlIHXK5n_MHJTup4s1McOuOQyv9KRozLzSs7FVFXymt8qEuHWtm67ipOsOFqrRbWFU9ve_U7cG8SXcb_bOx2eKSt0TmcTmeFqQ-qVXUbddqeb9DQNiRaz75tY61H37DjRs16x4SH341Hc-3YZXySqLYYXvqa3tLkwUZJTHwh1bGhZG6tVzKiphnX-2S1x0zoVB43ZWRcfuKP3bbUNFfjELVX3VmLtXya8moYIppEXRhhm8F0XvAyp14-7p_UmlBMpBmz9tI3SVPpOW7bMrvws1xWttYqXfDKjC4BN6Cop97sxypwZPENPSz_EjLVQPUetvHiBHp2XTIuXKGnKlqlly2zIllnLljkpTMeUsmU2ZMtUsvUKDb8mg3bHKktuWNzH3tKimLkRBasRZ0QEGeeuh1luZ9SlWIClRyg41CLAzHYyITDhAvS5yEhEmC8Ip94e2iluivwNMqnIGKO-LRjnfhhIXeBHPMwJBRvcZqGBPlaDl_IyH70sizJNFS8iClI9yAZ6X_eb6Qwsd3p8UmNfN9P5teQrhjjtjK9SB598aYdX45QYaE-BU3cE1AnBdmCgfUDr3ssfboG4-XcpPgY6qFBNS-2wSF1J7wdjHG5q1q2guuV-HC1y-H5TmYk0ijzHe6ALODi-dGkM9FqLy-YhwbUDRML9Pz3eAXqsKS9y3fAt2lnOV_k7sKSX7FDJ-08grMl5
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Postexposure+Rabies+Prophylaxis+Completed+in+1+Week+Preliminary+Study&rft.jtitle=Clinical+infectious+diseases&rft.au=SHANTAVASINKUL%2C+Prapimporn&rft.au=TANTAWICHIEN%2C+Thanphet&rft.au=WILDE%2C+Henry&rft.au=SAWANGVAREE%2C+Artikaya&rft.date=2010&rft.pub=Oxford+University+Press&rft.issn=1058-4838&rft.volume=50&rft.issue=1&rft.spage=56&rft.epage=60&rft_id=info:doi/10.1086%2F649211&rft.externalDBID=n%2Fa&rft.externalDocID=22337852
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon